Aktieanalys

Ultimovacs: Two-year OS Data from UV-103 - Redeye

{newsItem.title}

Redeye Publicerad: 20 Jun 2022 12:14

Redeye briefly comments on Ultimovacs communicating two-year overall survival data from UV-103. We judge that data broadly aligned with our expectations and leave our estimates unchanged.

Länk till analysen i sin helhet: https://www.redeye.se/research/846772/ultimovacs-two-year-os-data-from-uv-103?utm_source=finwire&utm_medium=RSS

Nyheter om Zelluna

Läses av andra just nu

Om aktien Zelluna

Senaste nytt